HeliDx Colon Cancer Assay

Colorectal cancer is the second leading cause of cancer-related mortality globally. The HeliDx Colon Cancer Assay is a versatile solution that analyses all clinically relevant mutations associated with colon cancer using formalin-fixed and paraffin-embedded (FFPE) samples.

Results can assist in identifying potential therapeutic options based on cancer specific features.

The HeliDx Colon Cancer Assay is designed for people that have a diagnosis of colorectal cancer and want to maximize diagnostic yieldand personalize their treatments.

The next step after diagnosis is usually to determine the specific genetic mutations that might be driving your cancer. This will give your doctor an idea of how the cancer will behave and can help determine which drugs are most likely to be effective, as there is a significant amount of research being done for targeted therapies for colorectal cancer based on mutation type.

The HeliDx Colon Cancer Assay covers all the clinically relevant mutations and gene fusions associated with colon cancer.
This includes variants in KRAS, NRAS, and BRAF.

The HelidX Colon Cancer Assay leverages Next Generation sequencing (NGS) technology to examine regions of the tumor genome that tend to get missed by single or hotspot biomarker tests.

The advantages of the HeliDx test are:

• Complete information of the common oncogenic drivers for colorectal cancer is obtained and will support clinical decision making more confidently.
• Analysis of your sample for multiple variants of interest using a single FFPE sample in a single experiment.
• Detection of single nucleotide changes, inversions, insertions, deletions, and multiple gene fusions in a single run.
• Optimized and accurate results since it includes a positive control design to confirm a true negative vs false negative result.
• Quick turnaround time of about 10 days.

With the HeliDx Colon Cancer Assay, when you visit the doctor for your initial biopsy, the same FFPE tissue sample used by the pathologist to detect cancer can be used for genetic testing.

• 10 ng of DNA and RNA are isolated, which can typically be obtained from 2–3 FFPE slides, enabling analysis of samples that may contain partially degraded or limited tumor material.
• The DNA/RNA library is prepared and sequenced on a NGS sequencer.
• Seamless integration of our informatics solutions with our sequencing platforms enables quick and intuitive analysis and reporting once the sequencing is completed.

To request the HeliDx Colon Cancer Assay, or for more information about the test, please feel free to call us at +971 (0)4 375 722 or fill in this form.

(*) required fields